ClinicalTrials.gg
CompletedNCT03863574EVIDENCES VIUpdated Oct 15, 2024Results posted

Saroglitazar Magnesium in the Treatment of Non-Alcoholic Steatohepatitis

A Phase 2 interventional study of Saroglitazar Magnesium 2mg and Saroglitazar Magnesium 4mg in Non Alcoholic Steatohepatitis, sponsored by Zydus Therapeutics Inc.. Completed at 6 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-15.

Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
387th of 460
16 · median 56
Started
2019
with 61 others
Phase 2
192 of 547
15 open now
Registered
277th of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 387th largest by enrollment of the 460 interventional ones that give a count, is one of 62 that started in 2019, is one of 192 in phase 2, and was the 277th registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of Saroglitazar Magnesium 2 mg and 4 mg in patients with NASH. This study will be initiated after obtaining the approvals of Institutional Ethics Committee/Institutional Review Board (IEC/IRB) and the local regulatory authority.

Read the detailed description

Patients clinically suspected of NASH will be invited for a screening programme for inclusion in the study. Patients will be screened according to the inclusion and exclusion criteria. Clinical evaluation will be conducted for baseline characteristics and anthropometry measurements such as body weight and height.

After clinical evaluations, all baseline safety and efficacy parameters will be recorded as per Visit Schedule. All laboratory collections will be performed following overnight fasting (at least 8 hrs).

Following confirmation of all clinical and laboratory inclusion and exclusion criteria, patients will continue into the screening period. During the screening period liver biopsy will be performed. However, if a biopsy was performed within 6 months the slides and biopsy material, or block, must be made available for baseline documentation. Such Patients, whose historical biopsy report is available, should not use medication suspected of having an effect on NASH from the 3 months prior to the screening.

Liver biopsy will be performed to confirm the diagnosis of NASH and record a baseline Non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS). The histological evidence of NASH is defined as NAS ≥ 4 with a minimum score of 1 for all of its three components [steatosis, hepatocyte ballooning and lobular inflammation].

Following confirmation of inclusion/exclusion criteria and upon histological confirmation of NASH by liver biopsy, patients will be enrolled into the study.

Eligible patients will be randomly assigned to receive Saroglitazar Magnesium 2 mg or 4 mg or placebo in a 2:2:1 ratio for 24 weeks.

Upon completion of 24 weeks of treatment, liver biopsy will be performed and the NAFLD Activity Score recorded.

03

Conditions studied

  • Non Alcoholic Steatohepatitis

Keywords

  • NASH
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients able to provide written for participation in this trial.
  2. Males or females, 18 to 75 years of age, both inclusive.
  3. Female must be either of non-child bearing potential (surgically sterilized at least 6 months prior to screening or ) or using one or more methods of .
  4. Histologic confirmation of NASH without cirrhosis (fibrosis stage 0, 1, 2, or 3) from liver performed either during the screening period or no more than 6 months prior to the first visit, with a NAS of ≥4 and a score of at least 1 in each (steatosis scored 0-3, ballooning scored 0-2, and lobular inflammation scored 0-3). If biopsy was performed within 6 months of screening, the slides, biopsy material or block should be available for baseline documentation. Such patients, whose historical biopsy report is available, should not use medications suspected of having an effect on NASH for at least 3 months prior to the screening.
  5. ≥25 kg/m\^2.
  6. For hypertensive patients, blood pressure must be controlled by a stable dose of antihypertensive medications for at least 3 months prior to screening (and the stable dose can be maintained throughout the study)
  7. Patients with type 2 diabetes mellitus may be included if they fulfil the following criteria;

    1. Stable therapeutic regimen as defined by no changes in oral agents or dose for at least 3 months before screening and the stable dose can be maintained throughout the study.
    2. ≤ 9.5%
  8. Patients agree to comply with the study procedure.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant and lactating female.
  2. Positive pregnancy test.
  3. Patients with history of myopathies or evidence of active muscle diseases.
  4. Patients with history of alcohol consumption of >30 gm/day for men, >20 gm/day for women for consecutive previous 2 years and/or drug abuse.
  5. Known allergy, sensitivity or intolerance to the study drug or formulation ingredients.
  6. Participation in an interventional clinical study and/or receipt of any medication within 3 months prior to screening.
  7. History of in the past 5 years and/or active neoplasm with the exception of superficial, non-melanoma, skin cancer.
  8. Any of the following laboratory values at screening:

    1. Direct >1.5 mg/dL,
    2. Serum albumin \<2.5 g/dL.
    3. Estimated (eGFR) \<60 mL/min/1.73m2.
    4. Serum (ALT) or aspartate aminotransferase (AST) >200 IU/L.
    5. Patient with (INR) >1.5.
    6. Creatinine kinase ≥ 1.5 (ULN).
    7. Lipase ≥ULN.
    8. Amylase ≥ ULN.
  9. Unstable cardiovascular disease, including:

    1. unstable angina, (i.e., new or worsening symptoms of coronary heart disease within the 3 months preceding screening), acute coronary syndrome within the 6 months preceding Screening, acute myocardial infarction within the 3 months preceding screening or heart failure of class (III - IV) or worsening congestive heart failure, or coronary artery intervention, within the 6 months preceding screening
    2. history of (within 3 months preceding Screening) or current unstable cardiac dysrhythmias
    3. uncontrolled hypertension (systolic blood pressure [BP] > 155 mmHg and/or diastolic BP > 95 mmHg)
    4. Stroke or within the 6 months preceding screening.
  10. Previous history of bladder disease and/or hematuria.
  11. Previous liver that demonstrated presence of cirrhosis or radiologic imaging consistent with cirrhosis or portal hypertension.
  12. Type 1 diabetes mellitus.
  13. Use of drugs that are known Cytochrome P4502C8 (CYP2C8) inhibitors/substrate.
  14. Use of drugs associated with a clinical or histological picture consistent with fatty liver disease or NASH for more than 12 consecutive weeks in the 1 year prior to start of the study; (these include amiodarone, tamoxifen, methotrexate, , anabolic steroids, tetracyclines, estrogens, valproate/valproic acid, chloroquine, anti- drugs).
  15. History of thyroid disease (hypothyroid patients who are euthyroid on thyroid hormone replacement can be included).
  16. History of, or current, cardiac dysrhythmias.
  17. History of bariatric surgery, or undergoing evaluation for bariatric surgery.
  18. Patients with a >10% weight loss in the 3 months prior to screening.
  19. History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the Investigator, unsuitable for the study (such as poorly controlled psychiatric disease, coronary artery disease, HIV or active gastrointestinal conditions that might interfere with drug absorption).
  20. Patients on any treatment with other drugs used for treatment of NASH [pentoxyphyllin, ursodeoxycholic acid, antioxidants such as vitamin E (>800 IU/day), glutathione, orlistat, betaine, incretin mimetics or non-prescribed complementary alternative medications (including dietary supplements, megadose vitamins, herbal preparations and special teas)] or any medicine in clinical trials for NASH. (However, patients who are taking stable dose of vitamin E for at least 3 months prior to screening will be enrolled in the study).
  21. History of other causes of chronic liver disease [, primary biliary cirrhosis, virus (HBV) and virus (HCV), Wilson disease, alpha-1-antitrypsin deficiency, hemochromatosis etc.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Saroglitazar Magnesium 2 mg

    Saroglitazar Magnesium 2 mg tablet orally once daily in the morning before breakfast for 24 weeks.

    Drug: Saroglitazar Magnesium 2mg

  • Experimental
    Saroglitazar Magnesium 4 mg

    Saroglitazar Magnesium 4 mg tablet orally once daily in the morning before breakfast for 24 weeks.

    Drug: Saroglitazar Magnesium 4mg

  • Placebo comparator
    Placebo

    Placebo tablet orally once daily in the morning before breakfast for 24 weeks.

    Drug: Placebos

Interventions

  • Patients randomly assigned to this group will receive Saroglitazar Magnesium 2 mg tablet orally once daily for 24 weeks.

  • Patients randomly assigned to this group will receive Saroglitazar Magnesium 4 mg tablet orally once daily for 24 weeks.

  • DrugPlacebos

    Patients randomly assigned to this group will receive Placebo tablet orally once daily for 24 weeks.

06

What researchers measure

Primary outcomes

  1. NAS Score (Nonalcoholic Fatty Liver Disease [NAFLD] Activity Score)

    The primary endpoint is to assess the changes in NAFLD Activity Score (NAS) at week 24 from baseline and with no worsening of fibrosis in NASH patients. NAFLD Activity Score Steatosis \<5% - 0 5% -33% - 1 \>33% -66% - 2 \>66% - 3 Lobular Inflammation No foci - 0 \<2 foci per 200 X field -1 2-4 foci per 200 X field - 2 \>4 foci per 200 X field - 3 Ballooning None - 0 Few balloon cells -1 Many cells/prominent ballooning - 2 Final NAFLD Activity Score = Steatosis Score + Lobular Inflammation Score + Ballooning Score Minimum score for NAS is 0 Maximum score for NAS is 8 Higher score represents the worse disease activity

    Time frame: Baseline to Week 24

Secondary outcomes

  1. To Evaluate the Percentage of Responders in the Treatment Groups.

    Responder is defined as a decrease from baseline of at least 2 points spread across at least 2 of the NAS components \[steatosis, hepatocyte ballooning, and lobular inflammation\] with no worsening of fibrosis.

    Time frame: Baseline to Week 24

  2. Percentage of Responders Defined by the Disappearance of Steatohepatitis.

    Percentage of responders defined by the disappearance of steatohepatitis

    Time frame: Baseline to Week 24

  3. Changes in the Stage of Steatosis, Lobular Inflammation and Ballooning.

    Changes in the stage of steatosis, lobular inflammation and ballooning by evaluating the NAS Score (Nonalcoholic fatty liver disease Activity Score) Steatosis \<5% - 0 5% -33% - 1 \>33% -66% - 2 \>66% - 3 Lobular Inflammation No foci - 0 \<2 foci per 200 X field -1 2-4 foci per 200 X field - 2 \>4 foci per 200 X field - 3 Ballooning None - 0 Few balloon cells -1 Many cells/prominent ballooning - 2 Higher score represents the worse disease activity

    Time frame: Baseline to Week 24

  4. Changes in the Stage of Fibrosis.

    Changes in the stage of fibrosis by evaluating the Fibrosis stages Fibrosis Score Definition None - 0 Perisinusoidal or periportal - 1 Mild, zone 3, perisinusoidal - 1A Moderate, zone3, perisinusoidal -1B Portal/periportal -1C Perisinusoidal and portal/periportal - 2 Bridging fibrosis - 3 Cirrhosis - 4 Higher score represents the worse disease activity

    Time frame: Baseline to Week 24

  5. Changes in the Liver Function Tests; (Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], Alkaline Phosphatases [ALP], and Gamma-glutamyl Transferase [GGT]).

    Liver function tests include ALT, AST, ALP, GGT

    Time frame: Baseline to Week 24

  6. Changes in the Liver Function Tests; Albumin and Total Protein

    Changes in albumin and total protein

    Time frame: Baseline to Week 24

  7. Changes in the Liver Function Tests; Direct Bilirubin

    Change in direct bilirubin

    Time frame: Baseline to Week 24

  8. Changes in the Lipid Profile.

    Evaluation of Lipid profile parameters

    Time frame: Baseline to Week 24

  9. Number of Participants Experiencing Adverse Events After Consuming Saroglitazar Magnesium 2 mg and 4 mg

    Number of Participants with Adverse Events.

    Time frame: Baseline to Week 24

  10. Changes in the Glycemic Control and Insulin Resistance; Fasting Plasma Glucose

    Evaluation of Fasting Plasma Glucose

    Time frame: Baseline to Week 24

  11. Changes in the Glycemic Control and Insulin Resistance; Hemoglobin A1c

    Evaluation of Hemoglobin A1c

    Time frame: Baseline to Week 24

  12. Changes in the Glycemic Control and Insulin Resistance; Insulin

    Evaluation of Insulin

    Time frame: Baseline to Week 24

  13. Changes in the Glycemic Control and Insulin Resistance: C-peptide

    Evaluation of C-peptide

    Time frame: Baseline to Week 24

  14. Changes in the Glycemic Control and Insulin Resistance: Homeostasis Model Assessment of Beta Cell Function (HOMA -β)

    Evaluation of HOMA of Beta Cell Function Homeostasis model assessment of beta cell function measures as following; HOMA -β = fasting insulin (μU/mL) ×360/{fasting glucose (mg/dL) - 63}. HOMA-B provides a quantitative estimate of beta-cell function. A lower HOMA-B value indicates reduced beta-cell function, which can be a sign of progressing towards or already having type 2 diabetes. Conversely, a higher HOMA-B value suggests better beta-cell functionality.

    Time frame: Baseline to Week 24

  15. Changes in the Glycemic Control and Insulin Resistance: HOMA of Insulin Resistance

    Evaluation of HOMA of Insulin Resistance Insulin Resistance Index measures insulin resistance, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance.

    Time frame: Baseline to Week 24

  16. Changes in the Glycemic Control and Insulin Resistance: Total Adiponectin

    Evaluation of Total Adiponectin

    Time frame: Baseline to Week 24

07

Results

Posted Oct 15, 2024

Participant flow

Participant flow — Overall Study
MilestoneSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Started673
Completed673
Not completed000

Outcome measures

PrimaryNAS Score (Nonalcoholic Fatty Liver Disease [NAFLD] Activity Score)

The primary endpoint is to assess the changes in NAFLD Activity Score (NAS) at week 24 from baseline and with no worsening of fibrosis in NASH patients. NAFLD Activity Score Steatosis \<5% - 0 5% -33% - 1 \>33% -66% - 2 \>66% - 3 Lobular Inflammation No foci - 0 \<2 foci per 200 X field -1 2-4 foci per 200 X field - 2 \>4 foci per 200 X field - 3 Ballooning None - 0 Few balloon cells -1 Many cells/prominent ballooning - 2 Final NAFLD Activity Score = Steatosis Score + Lobular Inflammation Score + Ballooning Score Minimum score for NAS is 0 Maximum score for NAS is 8 Higher score represents the worse disease activity

Time frame:
Baseline to Week 24
Reported as:
Mean · units on a scale
NAS Score (Nonalcoholic Fatty Liver Disease [NAFLD] Activity Score)
units on a scaleSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
NAS Score (Nonalcoholic Fatty Liver Disease [NAFLD] Activity Score)-1.50 ± 0.84-1.86 ± 1.57-1.33 ± 0.58
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.7689
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.6007
SecondaryTo Evaluate the Percentage of Responders in the Treatment Groups.

Responder is defined as a decrease from baseline of at least 2 points spread across at least 2 of the NAS components \[steatosis, hepatocyte ballooning, and lobular inflammation\] with no worsening of fibrosis.

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
To Evaluate the Percentage of Responders in the Treatment Groups.
ParticipantsSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
To Evaluate the Percentage of Responders in the Treatment Groups.431
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · Fisher Exact · p = 0.5238
  • Saroglitazar Magnesium 4 mg vs Placebo · Fisher Exact · p = >0.9999
SecondaryPercentage of Responders Defined by the Disappearance of Steatohepatitis.

Percentage of responders defined by the disappearance of steatohepatitis

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Percentage of Responders Defined by the Disappearance of Steatohepatitis.
ParticipantsSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Percentage of Responders Defined by the Disappearance of Steatohepatitis.560
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · Fisher Exact · p = 0.0476
  • Saroglitazar Magnesium 4 mg vs Placebo · Fisher Exact · p = 0.0333
SecondaryChanges in the Stage of Steatosis, Lobular Inflammation and Ballooning.

Changes in the stage of steatosis, lobular inflammation and ballooning by evaluating the NAS Score (Nonalcoholic fatty liver disease Activity Score) Steatosis \<5% - 0 5% -33% - 1 \>33% -66% - 2 \>66% - 3 Lobular Inflammation No foci - 0 \<2 foci per 200 X field -1 2-4 foci per 200 X field - 2 \>4 foci per 200 X field - 3 Ballooning None - 0 Few balloon cells -1 Many cells/prominent ballooning - 2 Higher score represents the worse disease activity

Time frame:
Baseline to Week 24
Reported as:
Mean · units on a scale
Changes in the Stage of Steatosis, Lobular Inflammation and Ballooning.
units on a scaleSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Changes in the stage of steatosis-0.50 ± 0.55-0.71 ± 0.76-0.33 ± 0.58
Changes in the stage of lobular inflammation-0.17 ± 0.41-0.29 ± 0.49-0.67 ± 0.58
Changes in the stage of ballooning-0.83 ± 0.41-0.86 ± 0.90-0.33 ± 0.58
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.6845
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.4625
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.1705
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.3122
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.1705
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.3877
SecondaryChanges in the Stage of Fibrosis.

Changes in the stage of fibrosis by evaluating the Fibrosis stages Fibrosis Score Definition None - 0 Perisinusoidal or periportal - 1 Mild, zone 3, perisinusoidal - 1A Moderate, zone3, perisinusoidal -1B Portal/periportal -1C Perisinusoidal and portal/periportal - 2 Bridging fibrosis - 3 Cirrhosis - 4 Higher score represents the worse disease activity

Time frame:
Baseline to Week 24
Reported as:
Mean · units on a scale
Changes in the Stage of Fibrosis.
units on a scaleSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Changes in the Stage of Fibrosis.-0.50 ± 0.84-0.43 ± 0.790.33 ± 0.58
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.1705
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.1740
SecondaryChanges in the Liver Function Tests; (Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], Alkaline Phosphatases [ALP], and Gamma-glutamyl Transferase [GGT]).

Liver function tests include ALT, AST, ALP, GGT

Time frame:
Baseline to Week 24
Reported as:
Mean · U/L
Changes in the Liver Function Tests; (Alanine Aminotransferase [ALT], Aspartate Aminotransferase [AST], Alkaline Phosphatases [ALP], and Gamma-glutamyl Transferase [GGT]).
U/LSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Change in ALT-22.83 ± 14.29-29.57 ± 26.76-14.67 ± 48.95
Change in AST-10.33 ± 5.32-16.29 ± 11.63-19.33 ± 47.44
Change in ALP-24.00 ± 9.92-23.86 ± 15.183.67 ± 5.13
Change in GGT-23.83 ± 18.55-28.43 ± 33.30-1.67 ± 19.50
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.8019
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.5396
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.7740
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.9221
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.0030
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.0177
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.1399
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.2384
SecondaryChanges in the Liver Function Tests; Albumin and Total Protein

Changes in albumin and total protein

Time frame:
Baseline to Week 24
Reported as:
Mean · g/dL
Changes in the Liver Function Tests; Albumin and Total Protein
g/dLSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Change in albumin-0.05 ± 0.22-0.04 ± 0.170.13 ± 0.12
Change in total protein-0.08 ± 0.400.09 ± 0.410.27 ± 0.06
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.2218
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.1483
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.0839
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.2895
SecondaryChanges in the Liver Function Tests; Direct Bilirubin

Change in direct bilirubin

Time frame:
Baseline to Week 24
Reported as:
Mean · mg/dL
Changes in the Liver Function Tests; Direct Bilirubin
mg/dLSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Changes in the Liver Function Tests; Direct Bilirubin-0.01 ± 0.03-0.01 ± 0.02-0.00 ± 0.02
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.6808
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.5351
SecondaryChanges in the Lipid Profile.

Evaluation of Lipid profile parameters

Time frame:
Baseline to Week 24
Reported as:
Mean · mg/dL
Changes in the Lipid Profile.
mg/dLSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Change in Triglyceride-40.33 ± 38.37-16.71 ± 44.31-6.00 ± 34.04
Change in Total Cholesterol11.17 ± 40.45-16.00 ± 31.12-0.33 ± 9.02
Change in Small dense LDL1.27 ± 15.99-9.29 ± 11.855.87 ± 6.66
Change in High-density Lipoprotein6.33 ± 14.85-0.14 ± 8.477.00 ± 4.36
Change in Low-density lipoprotein13.00 ± 34.89-12.57 ± 28.11-6.00 ± 5.29
Change in Very low-density lipoprotein-8.17 ± 7.41-3.29 ± 8.88-1.33 ± 6.51
Change in non-HDL Cholesterol4.83 ± 33.68-15.86 ± 29.23-7.33 ± 9.29
Change in Apo lipoprotein A110.50 ± 36.74-14.29 ± 26.987.33 ± 2.08
Change in Apo lipoprotein B1.00 ± 26.53-14.71 ± 21.04-1.33 ± 4.62
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.2329
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.7211
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.6520
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.4302
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.9432
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.2133
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.2446
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.7075
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.2195
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.7435
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.5702
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.6441
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.8415
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.0786
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.8878
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.3219
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.6557
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.0763
SecondaryNumber of Participants Experiencing Adverse Events After Consuming Saroglitazar Magnesium 2 mg and 4 mg

Number of Participants with Adverse Events.

Time frame:
Baseline to Week 24
Reported as:
Count of participants · Participants
Number of Participants Experiencing Adverse Events After Consuming Saroglitazar Magnesium 2 mg and 4 mg
ParticipantsSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Number of Participants Experiencing Adverse Events After Consuming Saroglitazar Magnesium 2 mg and 4 mg352
SecondaryChanges in the Glycemic Control and Insulin Resistance; Fasting Plasma Glucose

Evaluation of Fasting Plasma Glucose

Time frame:
Baseline to Week 24
Reported as:
Mean · mg/dL
Changes in the Glycemic Control and Insulin Resistance; Fasting Plasma Glucose
mg/dLSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Changes in the Glycemic Control and Insulin Resistance; Fasting Plasma Glucose2.67 ± 19.18-0.86 ± 41.107.67 ± 12.50
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.6988
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.7413
SecondaryChanges in the Glycemic Control and Insulin Resistance; Hemoglobin A1c

Evaluation of Hemoglobin A1c

Time frame:
Baseline to Week 24
Reported as:
Mean · percentage of HbA1c
Changes in the Glycemic Control and Insulin Resistance; Hemoglobin A1c
percentage of HbA1cSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Changes in the Glycemic Control and Insulin Resistance; Hemoglobin A1c-0.52 ± 0.65-0.09 ± 0.280.03 ± 0.35
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.2200
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.5798
SecondaryChanges in the Glycemic Control and Insulin Resistance; Insulin

Evaluation of Insulin

Time frame:
Baseline to Week 24
Reported as:
Mean · μIU/mL
Changes in the Glycemic Control and Insulin Resistance; Insulin
μIU/mLSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Changes in the Glycemic Control and Insulin Resistance; Insulin-1.05 ± 20.056.74 ± 15.348.13 ± 12.32
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.4981
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.8939
SecondaryChanges in the Glycemic Control and Insulin Resistance: C-peptide

Evaluation of C-peptide

Time frame:
Baseline to Week 24
Reported as:
Mean · ng/mL
Changes in the Glycemic Control and Insulin Resistance: C-peptide
ng/mLSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Changes in the Glycemic Control and Insulin Resistance: C-peptide-1.09 ± 2.260.08 ± 1.410.27 ± 0.95
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.3605
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.8394
SecondaryChanges in the Glycemic Control and Insulin Resistance: Homeostasis Model Assessment of Beta Cell Function (HOMA -β)

Evaluation of HOMA of Beta Cell Function Homeostasis model assessment of beta cell function measures as following; HOMA -β = fasting insulin (μU/mL) ×360/{fasting glucose (mg/dL) - 63}. HOMA-B provides a quantitative estimate of beta-cell function. A lower HOMA-B value indicates reduced beta-cell function, which can be a sign of progressing towards or already having type 2 diabetes. Conversely, a higher HOMA-B value suggests better beta-cell functionality.

Time frame:
Baseline to Week 24
Reported as:
Mean · percentage of HOMA of Beta Cell Function
Changes in the Glycemic Control and Insulin Resistance: Homeostasis Model Assessment of Beta Cell Function (HOMA -β)
percentage of HOMA of Beta Cell FunctionSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Changes in the Glycemic Control and Insulin Resistance: Homeostasis Model Assessment of Beta Cell Function (HOMA -β)-34.35 ± 84.4114.49 ± 358.0430.10 ± 46.15
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.2665
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.9133
SecondaryChanges in the Glycemic Control and Insulin Resistance: HOMA of Insulin Resistance

Evaluation of HOMA of Insulin Resistance Insulin Resistance Index measures insulin resistance, calculated by fasting insulin (μU/mL) multiplied by fasting glucose (mg/dL), and divided by a constant (405). A higher score indicates higher insulin resistance.

Time frame:
Baseline to Week 24
Reported as:
Mean · percentage of HOMA of Insulin Resistance
Changes in the Glycemic Control and Insulin Resistance: HOMA of Insulin Resistance
percentage of HOMA of Insulin ResistanceSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Changes in the Glycemic Control and Insulin Resistance: HOMA of Insulin Resistance0.45 ± 8.302.73 ± 5.772.34 ± 4.18
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.7267
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.9211
SecondaryChanges in the Glycemic Control and Insulin Resistance: Total Adiponectin

Evaluation of Total Adiponectin

Time frame:
Baseline to Week 24
Reported as:
Mean · μg/mL
Changes in the Glycemic Control and Insulin Resistance: Total Adiponectin
μg/mLSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Changes in the Glycemic Control and Insulin Resistance: Total Adiponectin1.84 ± 2.170.68 ± 3.281.50 ± 4.02
Statistical analysis
  • Saroglitazar Magnesium 2 mg vs Placebo · t-test, 2 sided · p = 0.8683
  • Saroglitazar Magnesium 4 mg vs Placebo · t-test, 2 sided · p = 0.7436

Adverse events

Collected over 24 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Saroglitazar Magnesium 2 mg0/6 (0%)0/6 (0%)3/6 (50%)
Saroglitazar Magnesium 4 mg0/7 (0%)2/7 (28.6%)5/7 (71.4%)
Placebo0/3 (0%)0/3 (0%)2/3 (66.7%)
Most frequent serious events
Most frequent serious events
EventSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
AppendicitisInfections and infestations0/61/70/3
BronchitisInfections and infestations0/61/70/3
AsthmaRespiratory, thoracic and mediastinal disorders0/61/70/3
Most frequent other events
Showing 10 of 37
Most frequent other events
EventSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Fungal infectionInfections and infestations0/60/71/3
Lower respiratory tract infectionInfections and infestations0/60/71/3
DiarrheaGastrointestinal disorders1/60/71/3
FlatulenceGastrointestinal disorders0/60/71/3
AmnesiaNervous system disorders0/60/71/3
FatigueGeneral disorders1/60/71/3
Rash pruriticSkin and subcutaneous tissue disorders0/60/71/3
InfluenzaInfections and infestations0/62/70/3
Tooth abscessInfections and infestations1/60/70/3
Urinary tract infectionInfections and infestations1/60/70/3

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Saroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlaceboTotal
Mean48.67 ± 9.9150.57 ± 16.4863.33 ± 8.0852.25 ± 13.46
Sex: Female, Male
Sex: Female, Male(Participants)Saroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlaceboTotal
Female56314
Male1102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Saroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlaceboTotal
Hispanic or Latino1315
Not Hispanic or Latino53210
Unknown or Not Reported0101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Saroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American1012
White57214
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)Saroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlaceboTotal
United States67316
Body Mass Index
Body Mass Index(kg/m^2)Saroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlaceboTotal
Mean37.32 ± 5.8537.89 ± 8.2737.67 ± 12.7637.63 ± 7.78
08

Study locations

6 sites
  • Southern Therapy and Advanced Research (STAR) LLC
    Jackson, Mississippi 39216, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • Digestive Health Research
    Hermitage, Tennessee 37076, United States
  • Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
09

References and documents

Publications

  • Siddiqui MS, Parmar D, Sheikh F, Sarin SK, Cisneros L, Gawrieh S, Momin T, Duseja A, Sanyal AJ. Saroglitazar, a Dual PPAR alpha/gamma Agonist, Improves Atherogenic Dyslipidemia in Patients With Non-Cirrhotic Nonalcoholic Fatty Liver Disease: A Pooled Analysis. Clin Gastroenterol Hepatol. 2023 Sep;21(10):2597-2605.e2. doi: 10.1016/j.cgh.2023.01.018. Epub 2023 Jan 31. PubMed 36731585 ↗
  • Siddiqui MS, Idowu MO, Parmar D, Borg BB, Denham D, Loo NM, Lazas D, Younes Z, Sanyal AJ. A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol. 2021 Dec;19(12):2670-2672. doi: 10.1016/j.cgh.2020.10.051. Epub 2020 Nov 2. PubMed 33152542 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2019 to primary completion in Mar 2020, 9 months.

Results were first posted in Oct 2024, 4 years 6 months after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 9 months is below that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 24, 2019
First posted
Mar 5, 2019
StartActual
Jun 12, 2019
Primary completionActual
Mar 20, 2020
CompletionActual
Mar 20, 2020
Results first posted
Oct 15, 2024
Last update
Oct 15, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 15, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03863574
Responsible party
Sponsor
First posted
Mar 5, 2019
Start date
Jun 12, 2019
Primary completion
Mar 20, 2020
Completion
Mar 20, 2020
Results posted
Oct 15, 2024
Last update
Oct 15, 2024

Study contacts

Deven V Parmar, MD,FACP,FCP
study director · Zydus Therapeutics Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Saroglitazar

Start the discussion